Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Boehringer Ingelheim
Baxter
McKesson
Dow

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for LEO Pharma A/S v. Tolmar Inc. (D. Del. 2010)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

LEO Pharma A/S v. Tolmar Inc. (D. Del. 2010)

Docket   Start Trial Date Filed 2010-04-06
Court District Court, D. Delaware Date Terminated 2013-02-12
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To
Parties LEO PHARMA A/S; RICHARD K. HERRMANN, -SM-; RICHARD K. HERRMANN, (SM); TEVA PHARMACEUTICALS INDUSTRIES LTD.; TOLMAR INC.
Patents 6,753,013
Attorneys Adam Wyatt Poff; Jack B. Blumenfeld; John C. Phillips , Jr.; Maryellen Noreika; Pilar Gabrielle Kraman
Firms Phillips, Goldman & Spence, P.A.
Link to Docket External link to docket
Small Molecule Drugs cited in LEO Pharma A/S v. Tolmar Inc.
The small molecule drugs covered by the patent cited in this case are   Start Trial and   Start Trial .

Details for LEO Pharma A/S v. Tolmar Inc. (D. Del. 2010)

Date Filed Document No. Description Snippet Link To Document
2011-10-28 106 Memorandum and Order the two patents-in-suit, U.S. Patent No. 6,753,013 (the “‘013 patent") and Reissued Patent No. RE …the best of its knowledge, the “013 patent and the RE ’706 patent are invalid or wi|| not be infringed…infringe the ‘013 patent and proposes to add claims for infringement of such patent. The motion is granted…RE 39,706 (the “RE ‘706 patent”). To|mar has submitted to the FDA ANDA Nos. 20-935 and 20-1615 (“the ANDAs…filed suit alleging infringement of the RE’706 patent, pursuant to 35 U.S.C. § 271(e)(2). Case 1:10- External link to document
2011-11-01 108 Notice of Service , Ph.D. Regarding the Invalidity of U.S. Patent No. 6,753,013 by Tolmar Inc..(Poff, Adam) (Entered: 11…Williard, Ph.D. Regarding the Invalidity of U.S. Patent No. RE39-706 and the Expert Report of Reza Fassihi… 12 February 2013 1:10-cv-00269 830 Patent None District Court, D. Delaware External link to document
2011-11-04 112 Patent/Trademark Report to Commissioner Pleading PATENT OR DATE OF PATENT TRADEMARK NO. OR TRADEMARK HOLDER OF PATENT OR TRADEMARK l 6,753,013 6/22…the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,753,013;. (Noreika, Maryellen…PLAINTIFF DEFENDANT PATENT OR DATE OF PATENT TRADEMARK NO. OR TRADEMARK HOLDER OF PATENT OR TRADEMARK 1 … TO_ Mail Stop 8 ' Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria,…FILING OR DETERMINATION OF AN‘ ACTION REGARDING A PATENT OR TRADEMARK In Compliance with 35 U.S.C. External link to document
2011-12-19 122 Notice of Service Relating to the Non-Infringement of U.S. Patent No. 6,753,013; Expert Report of Chad M. Reinstra, Ph.D….D. Relating to the Non-Infringement of U.S. Patent No. RE 39,706; Rebuttal Expert Report of Dr. Reza …Fassihi on the Issue of Non-Infringement of U.S. Patent No. RE39,706; and Expert Report of Jerry L. Atwood… Ph.D. Relating to the Non-Infringement of U.S. Patent No. RE39,706 by Tolmar Inc..(Kraman, Pilar) (Entered… 12 February 2013 1:10-cv-00269 830 Patent None District Court, D. Delaware External link to document
2012-01-17 125 Notice of Service Ph.D. Relating to the Invalidity of U.S. Patent No. 6,753,013; 2) Reply Expert Report of Reza Fassihi,…Fassihi, Ph.D. Regarding the Invalidity of U.S. Patent No. RE39,706; 3) Reply Expert Report of Dr. Gerald G.…Williard, Ph.D., Regarding the Invalidity of U.S. Patent No. RE39,706 by Tolmar Inc..(Kraman, Pilar) (Entered… 12 February 2013 1:10-cv-00269 830 Patent None District Court, D. Delaware External link to document
2012-05-04 196 Letter asserts a claim for patent infringement of U.S. Patent No. 6,753,013 (“the ‘013 patent”) related to Tolmar…allegations are not based on any existing patent claim or any patent claim that existed when the complaint…States patent number 6,665,797 is asserted in this action" A reexamination of the ’797 patent was initiated…allegations are not based on any existing patent claim or any patent claim that existed when the complaint… forward on that count in light of the Board of Patent Appeals and Interferences (“the Board”) decision External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Express Scripts
AstraZeneca
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.